Dr. Bruchez develops and commercializes research tools for bio-nanotechnology - an emerging field that creates or adapts materials and chemical processes to solve biological problems. As a graduate student, he modified quantum dots - nanometer-sized crystal particles - so that they could be used to tag proteins and label cells. After graduate school, he founded Quantum Dot Corporation, which grew these materials into a significant and commercially successful tool for single molecule biological detection and for multicolor analysis of cells, ultimately acquired by Invitrogen Corporation. At Carnegie Mellon University, Dr. Bruchez is investigating the limits of fluorescent microscopy and fluorescent probes at the National Technology Center for Networks and Pathways, a national resource for biological probe development, and is applying these tools to the study of how protein synthesis, trafficking and degradation is coordinated and regulated in biological systems.
Dr. Bruchez holds 17 patents, has published 28 peer-reviewed papers and has received numerous recognitions for his work. Science recognized his development of quantum dots for biological detection as one of the Top Ten Scientific Innovations of 2003. In 2006, Dr. Bruchez received the Lord Rank Prize for Optoelectronics for "realization of quantum dot nanocrystals as biological labels."
Dr. Bruchez received a B.S. in chemistry from the Massachusetts Institute of Technology, and a Ph.D. in physical chemistry from the University of California at Berkeley.
Carnegie Mellon University
4400 Fifth Ave.
Pittsburgh, PA 15213
Phone: (412) 268-9661
email: bruchez[AT]cmu[DOT]edu
Dr. Bruchez's Curriculum Vitae